Pharmacovigilance
Pharmacovigilance is a fundamental tool for Patient Safety.
Adium maintains processes, documented activities and procedures that ensure the functioning of the Pharmacovigilance System within the organization; in order to:
- Keep the risk profile of our pharmaceutical products updated.
- Comply with local regulatory requirements in Pharmacovigilance and with the requirements of our partners.
- Be one step ahead of the LATAM requests from regulatory agencies, and aligned with the EMA and USFDA guidelines on Good Pharmacovigilance Practices.
- Articulate with all stakeholders (internal and external) to add value and contribute to the business, focused on patient safety.
The Pharmacovigilance Department has a structure with personnel dedicated to the Pharmacovigilance System, made up of specifically trained health professionals who are part of the Medical Department.
Adium Central America & Caribbean has a Pharmacovigilance Officer and their corresponding Backup, both of whom are healthcare professionals responsible for maintaining the Pharmacovigilance System at the local level, following Corporate guidelines and complying with national regulations.
Adverse Event Reporting
One of the main activities of Pharmacovigilance is the reception, evaluation and communication of Adverse Events, Quality Claims or other safety information of interest associated with the use of our pharmaceutical products.
Adverse Event (AE):
Any adverse medical event in a patient who is administered a medicinal product and that does not necessarily have a causal relationship with this treatment. Therefore, an adverse event can be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom or disease temporarily associated with the use of a medicinal product, whether or not it is related to this medicinal product.
(Reference: ICH-E10 “Post-approval Safety Data Management: Definitions and Standard for Expedited Reporting E2D”.
Other security information of interest:
- Off-label use (outside the prospectus).
- Report of the usage results of the product during pregnancy.
- Exposure of the fetus to the product through the father.
- Report of adverse reactions during breastfeeding.
- Data report about the use of the product in children and elderly patients.
- Compassionate/Patient use reporting.
- Report of lack of efficacy. Report of presumed transmission of infectious agents.
- Report in relation to overdose, abuse and misuse, with or without adverse event.
- Report of medication errors (with or without exposure to the patient).
- Potential medication error.
- Second Primary Malignant Neoplasm.
- Report in the event of a public health emergency.
- Occupational Exposure.
- Accidental Exposure.
- Drug interaction.